The healthcare arm of Abu Dhabi-based tech company G42 is partnering with Amazon Web Services to launch new global genomics, proteomics, and biobanking service.
The deal allows G42 Healthcare to offer its sequencing, proteomics, and data analytics capabilities “to governments, population genome programs, and life science initiatives across the world,” it said in a statement.
Genomics is the study of genes, while proteomics is the large-scale study of proteins.
The Abu Dhabi firm claims to have extensive experience in the field, especially as it owns the region’s largest omics centre in the UAE capital that can deliver over 500,000 whole-genome sequences per year.
“Our experience in facilitating the world’s most comprehensive population genomics initiative in Abu Dhabi showcases our deep understanding of how to deliver at scale, from sample management to advanced analytics,” G42 Healthcare’s chief Ashish Koshy said.
He added: “Our goal with AWS is to take the capabilities that have taken years and significant resources to build, global and at speed.”
The term omics refers to a broad range of biological studies. It is typically related to using large-scale data to understand human life.
“The cooperation between G42 Healthcare and AWS is an exciting milestone to provide on-demand service for multi-omics data globally,” Jens Dommel, the Middle East of the AWS’ public health sector unit, said.
“Governments and researchers can benefit from democratized access to next-generation sequencing, proteomics, and data analytics, supported by the most flexible and secure cloud computing environment available today,” he added.
Follow us on
